Abstract
One therapeutic use for monoclonal antibody technology1 is the elimination of categories of unwanted cells by virtue of their distinct cell surface antigens. The efficiency of cell destruction by complement lysis or opsonization depends on a number of factors such as antibody specificity and isotype as well as certain properties of the target antigen2. In some instances cells can escape destruction by redistributing and eventually losing the antigen–antibody complexes from their surface3,4. This process, known as antigenic modulation, generally depends on bivalent antibody binding. Starting from the observation that rabbit antisera can be made more effective at killing tumour cells if they are first rendered univalent by limited proteolysis, we have now prepared a number of monovalent rat monoclonal antibodies to human cell-surface antigens. We find that these antibodies are no longer able to bring about modulation of their target antigens and have an enhanced facility for lysis with human complement. These special properties should greatly increase the therapeutic potential of monoclonal antibodies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kohler, G. & Milstein, C. Nature 256, 495–497 (1975).
Cobbold, S.P., Thierfelder, S. & Waldmann, H. Molecular Biology and Medicine 1, 285–304 (1984).
Glennie, M. J. & Stevenson, G. T. Nature 295, 712–714 (1982).
Boyse, E. A. & Old, L. J. A. Rev. Genet. 3, 269–291 (1969).
Galfre, G., Milstein, C. & Wright, B. Nature 277, 131–133 (1979).
Hoang, T. et al. Blood 61, 580–588 (1982).
Cobbold, S. P. thesis, Cambridge Univ. (1983).
Fust, G., Medgyesi, G. A., Bazin, H. & Gergely, J. Immun. Lett. 1, 249–253 (1980).
Hughes-Jones, N. C., Gorrick, B. D. & Howard, J. C. Eur. J. Immun. 13, 635–641 (1983).
Prentice, H. G. et al. Lancet i, 700–703 (1982).
Granger, S. et al. Br. J. Haemat. 50, 367–374 (1982).
Ritz, J. & Schlossman, S. F. Blood 59, 1–11 (1982).
Ritz, J., Pesando, J. M., Notis-McConarty, J., & Schlossman, S. F. J. Immun. 125, 1506–1514 (1980).
Hughes-Jones, N. C. & Ghosh, S. FEBS Lett. 128, 318–320 (1981).
Hale, G. et al. Blood 62, 873–882 (1983).
Cobbold, S. P. & Waldmann, H. J. Immun. Meth. 44, 125–133 (1981).
Hunt, S. V. & Fowler, M. H. Cell Tissue Kinet. 14, 445–464 (1981).
Gutman, G. A., Bazin, H., Rokhlin, O. V. & Nezlin, R. S. Transplantn Proc. 15, 1685–1686 (1983).
Springer, T. A., Bhattacharya, A., Cardoza, J. T. & Sanehez-Madrid, F. Hybridoma 1, 257–273 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cobbold, S., Waldmann, H. Therapeutic potential of monovalent monoclonal antibodies. Nature 308, 460–462 (1984). https://doi.org/10.1038/308460a0
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/308460a0
This article is cited by
-
Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy
Cancer Immunology Immunotherapy (1993)
-
Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine
Cancer Immunology Immunotherapy (1990)
-
Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment
The Indian Journal of Pediatrics (1990)
-
The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis
Springer Seminars in Immunopathology (1988)
-
Induction of transplantation tolerance by intraportal injection of allogeneic bone marrow cells
Transplant International (1988)
